1. Introduction {#sec1}
===============

Rheumatoid arthritis (RA) is a complex autoimmune disorder due to the involvement of many genetic, environmental, and stochastic elements in its etiology \[[@B1], [@B2]\]. It is characterized by continuous inflammation associated with altered expression of different proinflammatory (TNF*α*, IL-1, IL-17) and anti-inflammatory (IL-4, IL-10, IL-13, IL-35) cytokines and activation of B and T cells, which leads to the destruction of synovial joints and ultimately physical disability \[[@B3], [@B4]\]. Worldwide, RA affects 0.5 to 1% of the population \[[@B5]\]. RA prevalence does not differ significantly between rural and urban areas \[[@B6]\]. It can affect both sexes at any age, but data suggest that women are three times more prone than men \[[@B7]\]. There is a significant genetic susceptibility to RA with 50-60% heritability estimates \[[@B8]\]. Twin studies also revealed high concordance rates in monozygotic twins (12.3-15.4%) relative to dizygotic twins (3.5%), strongly indicating the presence of a genetic component in RA \[[@B9]\].

During the last two decades, many genetic studies, including genome-wide association studies (GWAS), have been conducted to understand the genetic basis of RA and this has led to the identification of more than 50 risk loci \[[@B10]\]. Besides *HLA-DRB1*, many non-*HLA* loci have been implicated that are involved in multiple functions/pathways including immune activation (NF-*κ*B signaling, JAK-STAT pathway, regulation, and activation of CD4^+^T-cells, complement activation), fibroblast differentiation and dedifferentiation, and bone modeling and repair \[[@B11], [@B12]\].

Thus far, the major focus of genetic studies on RA has largely been on Europeans or European-derived populations, with only limited data available on other populations \[[@B13]\], especially in South Asians \[[@B14]\]. In an effort to expand genetic studies on RA in South Asians and to further delineate its genetic basis, we sought to replicate 58 genome-wide significant single nucleotide polymorphisms (SNPs) from 58 loci previously implicated in Europeans or European-derived populations \[[@B15]--[@B18]\] in Pakistani population where there is the paucity of such data.

2. Material and Methods {#sec2}
=======================

2.1. Study Subjects {#sec2.1}
-------------------

A total of 1,959 subjects (1,222 cases, 737 controls) were included in our study. Blood samples and relevant clinical information were collected from three major public or private rheumatology clinics in Pakistan: Pakistan Institute of medical sciences (PIMS), Military hospital, and Rehmat Noor Clinic. All cases included in this study (mean age ± SD = 43.1 ± 12.33, 78.6% women) were clinically diagnosed by rheumatologists and met the American College of Rheumatology (ACR) 1987 classification criteria for RA \[[@B19]\]. All controls included in this study (mean age ± SD = 40.7 ± 12.49, 39.5% women) were recruited from the general population and were free of any autoimmune disease at the time of recruitment. A screening questionnaire was filled out and a written informed consent was obtained from each subject at the time of the recruitment. All blood samples were collected in EDTA tubes to avoid coagulation and processed shortly after the collection. The study was approved by the Institutional review board (IRB) of the University of Pittsburgh, USA (IRB no. PRO12110472).

2.2. Genomic DNA Extraction {#sec2.2}
---------------------------

Genomic DNA was extracted from whole blood using either the standard phenol-chloroform extraction method or GeneJET Whole Blood Genomic DNA Purification (Thermo Scientific USA) and quantified using the NanoDrop™ 2000 spectrophotometer (Thermo Scientific USA).

2.3. Genotyping {#sec2.3}
---------------

A total of 58 RA-associated genome-wide significant SNPs (*p* \< 5*E* − 08) was selected from the previously published GWAS in subjects of European ancestry ([Table 1](#tab1){ref-type="table"}). SNP genotyping was performed using either the TaqMan® (Applied Biosystems, Thermo Fisher Scientific) or iPLEX® Gold (Agena Bioscience) methods and following the manufacturer\'s design/order instructions and protocols. After the thermal cycling of the TaqMan® assays and DNAs on 384-well plates, the endpoint fluorescence reading was performed on a QuantStudio™ 12K Flex system (Applied Biosystems, Thermo Fisher Scientific). The iPLEX® Gold genotyping was performed in the Core laboratories of the University of Pittsburgh. 18% replicates were used to test genotyping consistency.

2.4. Statistical Analysis {#sec2.4}
-------------------------

Concordance to Hardy-Weinberg Equilibrium (HWE) was tested using the Chi-square goodness of fit test. Departure from HWE was considered at arbitrarily *p* \< 1*E* − 05. Logistic regression using an additive model and minor allele as the effect allele was employed for case-control association analysis using sex and age as covariates. The Benjamin Hochberg false discovery rate (FDR) was applied to correct for multiple testing \[[@B20]\]. *p* \< 0.05 was considered as suggestive evidence of association and FDR (*q* value) of \<0.20 as statistically significant as used in previous reports \[[@B21], [@B22]\]. All analyses were implemented in R, version 3.4.4.

2.5. Functional Annotations {#sec2.5}
---------------------------

To evaluate the potential biological significance of reported genome-wide significant SNPs, we used the Genotype-Tissue Expression (GTEx) database (<https://gtexportal.org/home/>) to search for expression quantitative trait loci (eQTL) in RA-relevant tissues and whole blood. We also used the RegulomeDB online database (<http://regulome.stanford.edu/>) to determine possible regulatory functions of the SNPs located in noncoding regions.

3. Results {#sec3}
==========

A total of 1,222 unrelated RA cases and 737 controls were recruited for this research study. The prevalence of RA was higher in females (78%) than males (22%), supporting the earlier data that females are more prone to RA \[[@B14]\].

Eight of the 58 genotyped SNPs failed the QC (quality control) during assay design (either iPLEX® Gold/TaqMan® or both). The genotype distribution of all QC-passed 50 SNPs adhered to the HWE. The association analyses results in our Pakistani sample are presented in [Table 2](#tab2){ref-type="table"}. Fourteen SNPs showed nominal significance at *p* \< 0.05 and FDR of ≤0.20.

We found the same direction of association where the minor allele showed the same risk or protective effect as compared to the previous findings on the tested allele (major or minor). In our data, *LINC00824*/rs1516971 showed the most significant association (*p* = 4.73*E* − 06). The second most significant SNP was *PADI4*/rs2240336 (*p* = 5.00*E* − 05) followed by *CEP57*/rs4409785 (*p* = 1.03*E* − 03), *CTLA4*/rs3087243 (*p* = 1.23*E* − 03), *STAT4*/rs13426947 (*p* = 2.59*E* − 03), and *HLA-B-MICA*/rs2596565 (*p* = 4.53*E* − 03). Eight other SNPs showed marginal significance: *C5orf30*/rs26232 (*p* = 3.73*E* − 02), *CCL21*/rs951005 (*p* = 2.75*E* − 02), *GATA3*/rs2275806 (*p* = 4.02*E* − 02), *VPS37C*/rs595158 (*p* = 3.10*E* − 02), *HLA-DRB1*/rs660895 (*p* = 4.02*E* − 02), *EOMES*/rs3806624 (*p* = 3.54*E* − 02), *SPRED2*/rs934734 (*p* = 4.24*E* − 02), and *RUNX1*/rs9979383 (*p* = 3.48*E* − 02). [Figure 1](#fig1){ref-type="fig"} shows the distribution of tested SNPs across the genome where the SNPs with *p* value \< 0.05 are labeled.

Next, we examined the functional significance of all 50 SNPs using the GTEx and RegulomeDB databases. [Table 3](#tab3){ref-type="table"} shows the category summaries of RegulomeDB scores, and [Table 4](#tab4){ref-type="table"} shows 14 SNPs that had a RegulomeDB score of ≤3, indicating strong evidence of potential regulatory role. SNPs falling in this category have more likelihood to affect the binding of transcriptional factors. Out of these fourteen SNPs, only five (*HLA-B/MICA*/rs2596565, *HLA-DRB1*/rs660895, *C5orf30*/rs26232, *CTLA4*/rs3087243, and *RUNX1*/rs9979383) had *p* \< 0.05 in our association results. *SYNGR1*/rs909685 had the top RegulomeDB score of 1b followed by *FADS2*/rs968567, *CD40*/rs4810485, *CCR6*/rs3093023, *HLA-B/MICA/*rs2596565, and *HLA-DRB1*/rs660895 with a score of 1f. The latter two SNPs (*HLA-B/MICA/*rs2596565 and *HLA-DRB1*/rs660895) were significant in our sample (*p* = 0.0045 and *p* = 0.0402) and based on RegulomeDB, both SNPs are eQTL for *HLA-DQA1*. While *HLA-DRB1*/rs660895 affects the binding of two proteins (BCLAF1 and POLR2A), no such evidence was found for *HLA-B/MICA/*rs2596565. *SYNGR1*/rs909685 is an intronic variant, which falls in the p53decamer binding motif and affects the binding of five different proteins (MAX, MYC, PAX5, TRIM28, and EBF1). *FADS2*/rs968567 is also an intronic variant and it affects the binding of twenty-eight proteins, including MAX, POLR2A, NFKB1, and NFIC. The binding of these proteins is also affected by the *CD40*/rs4810485 variant. An intronic *CCR6*/rs3093023 variant falls in the Oct-1 binding motif and is eQTL for *CCR6.*

GTEx data eQTL showed the lowest p-eQTL (2.59*E*-34) for *FADS2*/rs968567 that affects *FADS2* gene expression in transformed fibroblast cells; the same variant also affects *TMEM258* (p − eQTL = 3.43*E* − 08), *ZBTB3* (p − eQTL = 0.0168), *MYRF* (p − eQTL = 0.0207), *DAGLA* (p − eQTL = 0.0246), and *RAB3IL1* (p − eQTL = 0.0247). In transformed fibroblast cells, *LINC00824*/rs1516971 was a weak eQTL (*p* = 0.0157) for *RP11-89M16.1.* No data was available for *CTLA*4/rs3087243 in GTEx.

*STAT4*/rs13426947 was eQTL for *STAT4*, *AC005540.3*, and *RP11-647K16.1* in EBV-transformed lymphocyte cells. HLA-B/MICA/rs2596565 was eQTL for multiple immune-related genes including *C4A*, *C4B*, *HLA-S*, *HLA-B*, *HLA-C*, and *MICA* in all three tested tissues. *C5orf30*/rs26232 showed the strongest eQTL (p − eQTL = 1.72*E* − 19) with PPIP5K2 only in whole blood. Additional details of GTEx data are given in supplementary Table [S1](#supplementary-material-1){ref-type="supplementary-material"}.

4. Discussion {#sec4}
=============

There have been a number of genome-wide association studies on RA over the past decade that have resulted in the identification of many RA susceptibility loci, thus improving our understanding of the complex genetic underpinning of RA \[[@B15]--[@B17]\]. Most of the recently published GWAS have been conducted on Europeans and North Americans, which have identified many new RA risk loci and replicated and confirmed the previously reported putative risk loci. Many of these reported risk loci are shared among different ethnic groups, while some are specific to certain populations \[[@B23]\]. Replication studies across different ethnic groups are necessary to better understand the globe-wide population specificity of these established RA risk loci and guide future directions. Since South Asians, including the Pakistani population, have significant European ancestry \[[@B24], [@B25]\], we chose European originated GWAS-implicated SNPs for replication in Pakistanis. For this purpose, we enrolled 1,959 unrelated RA cases and controls from two public and private Rheumatology facilities, where people from different demographic regions of Pakistan visit for treatment, and we successfully genotyped 50 GWAS---implicated SNPs in those subjects.

In our data set, rs1516971 was the most significant SNP (*p* = 4.73*E* − 06), which is an intronic variant in the *LINC00824* gene at chromosome 8q24.21. Previously, this variant has also been reported in a trans-ethnic association study of RA (*p* = 1.3*E* − 10) \[[@B16]\]. Another SNP (rs6651252) from the same region, which is in complete LD (*r*^2^ = 1.00) with rs1516971, has also been reported to be associated with RA and Crohn\'s disease \[[@B15], [@B26], [@B27]\]. GTEx expression data suggests that rs1516971 affects the expression of *RP11-89M16.1* at chromosome 8 in transformed fibroblast cells (p − eQTL = 0.0157).

The second most significant SNP in our data was rs2240336 (*p* = 5.00*E* − 05), which is present in the 9^th^ intron of *PADI4* at chromosome 1p36. *PADI4* is one of the most important RA susceptibility loci in multiple ethnic groups, including Europeans, Asians, and Latin Americans \[[@B28], [@B29]\]. Another SNP in this region, rs2301888 that is in strong LD (*r*^2^ = 0.8) with rs2240336, has also been reported to be associated with RA in Europeans and Koreans \[[@B30]\]. However, a study on Iranian population found no significant association of two other SNPs (rs11203367 and rs874881) in the *PADI4* region with RA, which are not in strong LD (*r*^2^ \< 0.8) with rs2240336 \[[@B31]\]. GTEx expression data showed that rs2240336 is eQTL for *RP4-798A10.2* (p − eQTL = 0.0191) and *PADI3* (p − eQTL = 0.0203) in EBV transformed lymphocytes. The rs2240336 SNP also controls the expression of *FBXO42* (p − eQTL = 0.00526) in transformed fibroblasts. The third most important SNP in our data is *CEP57*/rs4409785 (p = 1.03E − 03), which is an intergenic variant on chromosome 11q21. This SNP has also been reported to be associated with other immune-related diseases such as multiple sclerosis, vitiligo, and Graves\' disease \[[@B32]--[@B34]\]. In GTEx expression data, rs4409785 was eQTL for *JRKL* (p − eQTL = 0.037) in EBV-transformed lymphocytes, and for *AP001877.1* (p − eQTL = 0.0188), and *MAML2* (p − eQTL = 0.034) in transformed fibroblast cells.

Among the reported genome-wide significant SNPs that did not show significant association in our sample, the top functional ones based on the GTEx and RegulomeDB database included *SYNGR1*/rs909685, *FADS2*/rs968567, *CD40*/rs4810485, *CCR6*/rs3093023, and *IKZF3*/rs12936409. *SYNGR1*/rs909685 has a RegulomeDB score of 1b and is a strong eQTL for *SYNGR1* in EBV-transformed lymphocytes (p − eQTL = 3.74*E* − 14) and whole blood (p − eQTL = 5.68*E* − 21). *FADS2*/rs968567 has a RegulomeDB score of 1f and is eQTL for *FADS2* in EBV-transformed lymphocytes (p − eQTL = 2.05*E* − 05), whole blood and (p − eQTL = 1.86*E* − 71) transformed fibroblasts (p − eQTL = 2.59*E* − 34). *CD40*/rs4810485 also has a high RegulomeDB score of 1f and is strong eQTL for *CD40* in whole blood (p − eQTL = 1.33*E* − 09) and transformed fibroblasts (p − eQTL = 8.58*E* − 11) but weak eQTL for *CD40* in EBV-transformed lymphocytes (p − eQTL = 0.0272). *CCR6*/rs3093023 with RegulomeDB score of 1f was the strongest eQTL for *RNASET2* in transformed fibroblasts (p − eQTL = 1.08*E* − 16) and whole blood (p − eQTL = 1.31*E* − 15) with no data reported for EBV-transformed lymphocytes in GTEx. *IKZF3*/rs12936409 was a strong eQTL for *ORMDL3* in all three tested tissues. In GTEx expression data, rs12936409 was found to control the expression of *GSDMA*, *GSDMB*, and *ORMDL3* in all tested cells and whole blood.

5. Conclusions {#sec5}
==============

We were able to successfully replicate 14 of 50 SNPs selected from previously published GWAS results in European populations in our unique Pakistani population. These findings suggest that there is a sharing of RA risk loci among different population groups. A weakness of our study is the availability of relatively small-sized sample, which may have prevented 36 SNPs from achieving the significance threshold, although they showed a trend for the same directional effects as the reported ones. Further studies using larger samples may help to identify and replicate more RA risk loci in the Pakistani population.
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###### 

S1: additional details of GTEx data.

###### 

Click here for additional data file.

![Annotated 50 tested SNPs. SNPs with *p* value \< 0.05 are shown above the dotted line.](DM2020-1910215.001){#fig1}

###### 

List of selected GWAS-implicated RA SNPs examined in this study.

  SNP          Locus      Chromosomal location (GRCh38)   Variant type          Gene             Reference
  ------------ ---------- ------------------------------- --------------------- ---------------- ------------
  rs2228145    1q21       154454494                       Missense variant      *IL6R*           \[[@B15]\]
  rs2105325    1q25.1     173380586                       Intron variant        *LOC100506023*   \[[@B16]\]
  rs2843401    1p36       2596694                         Intron variant        *MMEL1*          \[[@B15]\]
  rs28411352   1p34.3     37812907                        3 prime UTR variant   *MTF1*           \[[@B16]\]
  rs883220     1p34       38151199                        Intron variant        *LOC105378654*   \[[@B15]\]
  rs2476601    1p13       113834946                       Missense variant      *PTPN22*         \[[@B15]\]
  rs6732565    2q13       110850255                       Intron variant        *ACOXL*          \[[@B16]\]
  rs11676922   2q11       100190478                       Intergenic            *AFF3*           \[[@B17]\]
  rs6715284    2q33.1     201289674                       Intron variant        *ALS2CR12*       \[[@B16]\]
  rs3087243    2q33       203874196                       Downstream variant    *CTLA4*          \[[@B17]\]
  rs34695944   2p16       60897715                        Intron variant        *REL*            \[[@B15]\]
  rs934734     2p14       65368452                        Intron variant        *SPRED2*         \[[@B17]\]
  rs13426947   2q32       191068528                       Intron variant        *STAT4*          \[[@B15]\]
  rs3806624    3p24.1     27723132                        Upstream variant      *EOMES*          \[[@B16]\]
  rs9826828    3q22.3     136683218                       Intron variant        *STAG1*          \[[@B16]\]
  rs4452313    3p24.3     17005540                        Intron variant        *PLCL2*          \[[@B16]\]
  rs13315591   3p14       58571114                        Intron variant        *FAM107A*        \[[@B17]\]
  rs874040     4p15       26106575                        Upstream variant      *RBPJ*           \[[@B17]\]
  rs2664035    4p11       48218822                        Intron variant        *TEC*            \[[@B16]\]
  rs71624119   5q11       56144903                        Intron variant        *ANKRD55*        \[[@B15]\]
  rs26232      5q21       103261019                       Intron variant        *C5orf30*        \[[@B17]\]
  rs3093023    6q27       167120802                       Intron variant        *CCR6*           \[[@B16]\]
  rs2234067    6p21.31    36387877                        Upstream variant      *ETV7*           \[[@B16]\]
  rs6920220    6q23       137685367                       Upstream variant      *TNFAIP3*        \[[@B15]\]
  rs2596565    6p21.33    31385552                        Upstream variant      *HLA-B/MICA*     \[[@B18]\]
  rs6910071    6p21       32315077                        Intron variant        *TSBP1*          \[[@B17]\]
  rs660895     6p21       32609603                        Intron variant        *HLA-DRB1*       \[[@B14]\]
  rs4272       7q21.2     92607515                        3 prime UTR variant   *CDK6*           \[[@B16]\]
  rs10488631   7q32       128954129                       Downstream variant    *IRF5*           \[[@B17]\]
  rs67250450   7p15.1     28135367                        Intron variant        *JAZF1*          \[[@B16]\]
  rs678347     8q22.3     101451374                       Upstream variant      *GRHL2*          \[[@B16]\]
  rs1516971    8q24.21    128529854                       Intron variant        *LINC00824*      \[[@B16]\]
  rs998731     8q21.13    80183160                        Intron variant        *TPD52*          \[[@B16]\]
  rs951005     9p13       34743684                        Intergenic            *CCL21*          \[[@B17]\]
  rs12764378   10q21      62040245                        Intron variant        *ARID5B*         \[[@B15]\]
  rs2275806    10p14      8053377                         Intron variant        *GATA3*          \[[@B15]\]
  rs706778     10p15      6056986                         Intron variant        *IL2RA*          \[[@B17]\]
  rs595158     11q12      61142109                        Intron variant        *VPS37C*         \[[@B15]\]
  rs4409785    11q21      95578258                        Intergenic/unknown    *CEP57*          \[[@B16]\]
  rs773125     12q13.2    56001170                        Intron variant        *SUOX*           \[[@B16]\]
  rs1950897    14q24.1    68293424                        Intron variant        *RAD51B*         \[[@B16]\]
  rs8043085    15q14      38535939                        Intron variant        *RASGRP1*        \[[@B15]\]
  rs8026898    15q23      69699078                        Intergenic/unknown    *TLE3*           \[[@B15]\]
  rs13330176   16q24      85985481                        Intergenic/unknown    *IRF8*           \[[@B15]\]
  rs4780401    16p13.13   11745470                        Upstream variant      *TXNDC11*        \[[@B16]\]
  rs12936409   17q12      39887396                        Intergenic/unknown    *IKZF3*          \[[@B15]\]
  rs34536443   19p13      10352442                        Missense variant      *TYK2*           \[[@B15]\]
  rs4810485    20q13      46119308                        Intron variant        *CD40*           \[[@B17]\]
  rs9979383    21q22      35343463                        Intron variant        *RUNX1*          \[[@B15]\]
  rs1893592    21q22.3    42434957                        Intron variant        *UBASH3A*        \[[@B16]\]
  rs909685     22q13.1    39351666                        Intron variant        *SYNGR1*         \[[@B16]\]
  rs2240336    1p36       17347907                        Intron variant        *PADI4*          \[[@B16]\]
  rs10175798   2p23.1     30226728                        Upstream variant      *LBH*            \[[@B16]\]
  rs968567     11q12.2    61828092                        Intron variant        *FADS2*          \[[@B16]\]
  rs10774624   12q24.12   111395984                       Upstream variant      *LINC02356*      \[[@B16]\]
  rs9603616    13q14.11   39793932                        Downstream variant    *COG6*           \[[@B16]\]
  rs73194058   21q22.11   33391982                        Intergenic/unknown    *IFNGR2*         \[[@B16]\]
  rs2834512    21q22      34539301                        Intron variant        *RCAN1*          \[[@B15]\]

###### 

Association analysis results for GWAS-implicated RA SNPs in the Pakistani population.

  Gene/SNP                  Major allele   Minor allele   MAF     Reported GWAS *p* value   Nominal *p* value in Pakistanis   OR (95% CI)         FDR (*q*)
  ------------------------- -------------- -------------- ------- ------------------------- --------------------------------- ------------------- ------------
  *LINC00824*/rs1516971     T              C              0.099   3.20*E*-11                4.73*E*-06                        0.57 (0.45, 0.73)   2.37*E*-04
  *PADI4*/rs2240336         C              T              0.452   5.9*E*−9                  5.00*E*-05                        0.74 (0.64, 0.86)   1.25*E*-03
  *CEP57*/rs4409785         T              C              0.262   3.60*E*-09                1.03*E*-03                        1.33 (1.12, 1.58)   1.54*E*-02
  *CTLA4*/rs3087243         A              G              0.422   1.2*E*−8                  1.23*E*-03                        1.28 (1.1, 1.49)    1.54*E*-02
  *STAT4*/rs13426947        G              A              0.238   7.2*E*−10                 2.59*E*-03                        1.31 (1.1, 1.56)    2.59*E*-02
  *HLA-B/MICA*/rs2596565    G              A              0.119   9.26*E*-09                4.53*E*-03                        1.4 (1.11, 1.77)    3.77*E*-02
  *C5orf30*/rs26232         C              T              0.181   4.10*E*-08                3.73*E*-02                        0.83 (0.69, 0.99)   1.52*E*-01
  *CCL21*/rs951005          A              G              0.248   3.90*E*-10                2.75*E*-02                        0.82 (0.69, 0.98)   1.52*E*-01
  *GATA3*/rs2275806         A              G              0.397   4.6*E*−8                  4.02*E*-02                        1.17 (1.01, 1.36)   1.52*E*-01
  *VPS37C*/rs595158         A              C              0.320   3.4*E*−8                  3.10*E*-02                        1.19 (1.02, 1.38)   1.52*E*-01
  *HLA-DRB1*/rs660895       A              G              0.111   \<1*E*-300                4.02*E*-02                        1.27 (1.01, 1.59)   1.52*E*-01
  *EOMES*/rs3806624         G              A              0.262   2.80*E*-08                3.54*E*-02                        0.84 (0.71, 0.99)   1.52*E*-01
  *SPRED2*/rs934734         A              G              0.406   5.30*E*-10                4.24*E*-02                        1.17 (1.01, 1.35)   1.52*E*-01
  *RUNX1*/rs9979383         T              C              0.300   5.0*E*−10                 3.48*E*-02                        0.84 (0.72, 0.99)   1.52*E*-01
  *IL2RA*/rs706778          T              C              0.458   1.40*E*-11                6.21*E*-02                        0.87 (0.75, 1.01)   2.07*E*-01
  *LOC105378654*/rs883220   C              A              0.212   2.1*E*−8                  1.08*E*-01                        0.87 (0.73, 1.03)   3.17*E*-01
  *IRF5*/rs10488631         T              C              0.196   4.20*E*-11                1.07*E*-01                        1.16 (0.97, 1.39)   3.17*E*-01
  *RCAN1*/rs2834512         G              A              0.160   2.1*E*−8                  1.39*E*-01                        0.86 (0.71, 1.05)   3.86*E*-01
  *ARID5B*/rs12764378       G              A              0.241   4.5*E*−10                 1.64*E*-01                        1.13 (0.95, 1.34)   4.33*E*-01
  *TYK2*/rs34536443         G              C              0.010   2.3*E*−14                 1.73*E*-01                        0.62 (0.31, 1.23)   4.33*E*-01
  *IL6R*/rs2228145          A              C              0.323   1.3*E*−8                  1.89*E*-01                        0.9 (0.77, 1.05)    4.50*E*-01
  *PTPN22*/rs2476601        G              A              0.016   7.5*E*−77                 2.21*E*-01                        1.47 (0.79, 2.73)   4.93*E*-01
  *SYNGR1*/rs909685         T              A              0.480   6.40*E*-12                2.27*E*-01                        1.09 (0.95, 1.26)   4.93*E*-01
  *MTF1*/rs28411352         C              T              0.222   5.90*E*-09                2.42*E*-01                        1.11 (0.93, 1.32)   5.05*E*-01
  *CCR6*/rs3093023          G              A              0.425   1.50*E*-11                2.70*E*-01                        1.09 (0.94, 1.26)   5.19*E*-01
  *ALS2CR12*/rs6715284      C              G              0.185   2.50*E*-09                2.61*E*-01                        1.11 (0.92, 1.35)   5.19*E*-01
  *UBASH3A*/rs1893592       A              C              0.241   9.80*E*-09                3.11*E*-01                        0.92 (0.77, 1.08)   5.75*E*-01
  *IRF8*/rs13330176         T              A              0.243   4.0*E*−8                  4.04*E*-01                        0.93 (0.78, 1.11)   6.13*E*-01
  *PLCL2*/rs4452313         A              T              0.492   5.2*E*-11                 3.76*E*-01                        1.07 (0.92, 1.24)   6.13*E*-01
  *ACOXL*/rs6732565         G              A              0.444   9.40*E*-09                4.15*E*-01                        0.94 (0.81, 1.09)   6.13*E*-01
  *GRHL2*/rs678347          A              G              0.425   7.30*E*-10                4.17*E*-01                        1.06 (0.92, 1.23)   6.13*E*-01
  *TLE3*/rs8026898          G              A              0.303   9.16.*E*-14               3.50*E*-01                        0.93 (0.79, 1.09)   6.13*E*-01
  *RASGRP1*/rs8043085       G              T              0.280   1.4*E*−10                 3.64*E*-01                        1.08 (0.92, 1.27)   6.13*E*-01
  *REL*/rs34695944          T              C              0.112   1.4*E*−10                 4.05*E*-01                        1.1 (0.88, 1.39)    6.13*E*-01
  *COG6*/rs9603616          C              T              0.260   2.80*E*-11                4.47*E*-01                        0.94 (0.8, 1.11)    6.38*E*-01
  *TPD52*/rs998731          T              C              0.434   6.60*E*-09                5.04*E*-01                        0.95 (0.82, 1.1)    7.00*E*-01
  *TNFAIP3*/rs6920220       G              A              0.132   2.3*E*−13                 5.33*E*-01                        1.07 (0.86, 1.34)   7.20*E*-01
  *CD40*/rs4810485          G              T              0.250   2.8*E*−9                  6.03*E*-01                        0.96 (0.81, 1.13)   7.94*E*-01
  *RAD51B*/rs1950897        T              C              0.208   5.00*E*-08                7.02*E*-01                        1.04 (0.86, 1.24)   8.98*E*-01
  *FAM107A*/rs13315591      T              C              0.043   4.60*E*-08                7.25*E*-01                        1.06 (0.75, 1.51)   8.98*E*-01
  *MMEL1*/rs2843401         C              T              0.461   6.6*E*−9                  7.80*E*-01                        1.02 (0.88, 1.18)   8.98*E*-01
  *RBPJ*/rs874040           G              C              0.159   1.00*E*-16                8.20*E*-01                        0.98 (0.81, 1.18)   8.98*E*-01
  *IKZF3*/rs12936409        C              T              0.392   2.8*E*−9                  8.19*E*-01                        0.98 (0.85, 1.14)   8.98*E*-01
  *LBH*/rs10175798          A              G              0.474   4.20*E*-08                8.46*E*-01                        1.01 (0.88, 1.17)   8.98*E*-01
  *LINC02356*/rs10774624    A              G              0.138   6.90*E*-09                8.38*E*-01                        0.98 (0.79, 1.2)    8.98*E*-01
  *FADS2*/rs968567          G              A              0.084   1.80*E*-08                8.62*E*-01                        0.98 (0.75, 1.27)   8.98*E*-01
  *AFF3*/rs11676922         T              A              0.485   1.00*E*-14                7.91*E*-01                        0.98 (0.85, 1.14)   8.98*E*-01
  *CDK6*/rs4272             A              G              0.083   1.2*E*-8                  7.64*E*-01                        0.96 (0.74, 1.24)   8.98*E*-01
  *TEC*/rs2664035           G              A              0.256   3.30*E*-08                9.54*E*-01                        1 (0.84, 1.17)      9.70*E*-01
  *TXNDC11*/rs4780401       T              G              0.430   8.70*E*-09                9.70*E*-01                        1 (0.86, 1.16)      9.70*E*-01

###### 

RegulomeDB score description.

  Score                                                                    Description
  ------------------------------------------------------------------------ -----------------------------------------------------------------------------
  Likely to affect binding and linked to the expression of a gene target   
  1a                                                                       eQTL + TF binding + matched TF motif + matched DNase footprint + DNase peak
  1b                                                                       eQTL + TF binding + any motif + DNase footprint + DNase peak
  1c                                                                       eQTL + TF binding + matched TF motif + DNase peak
  1d                                                                       eQTL + TF binding + any motif + DNase peak
  1e                                                                       eQTL + TF binding + matched TF motif
  1f                                                                       eQTL + TF binding/DNase peak
  Likely to affect binding                                                 
  2a                                                                       TF binding + matched TF motif + matched DNase footprint + DNase peak
  2b                                                                       TF binding + any motif + DNase footprint + DNase peak
  2c                                                                       TF binding + matched TF motif + DNase peak
  Less likely to affect binding                                            
  3a                                                                       TF binding + any motif + DNase peak
  3b                                                                       TF binding + matched TF motif
  Minimal binding evidence                                                 
  4                                                                        TF binding + DNase peak
  5                                                                        TF binding or DNase peak
  6                                                                        Motif hit
  7                                                                        No data available

###### 

Details of study SNPs (RegulomeDB Score ≤ 3) with putative regulatory functions.

  SNP                       Chr.    Score   eQTL                                                                                Bound protein                                                                                                                                                                              Motifs
  ------------------------- ------- ------- ----------------------------------------------------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ----------------------------------------------------------
  *SYNGR1*/rs909685         chr22   1b      SYNGR1                                                                              MAX, MYC, PAX5, TRIM28, EBF1                                                                                                                                                               p53decamer
  *FADS2*/rs968567          chr11   1f      NXF1                                                                                CTCF, E2F4, EP300, ETS1, FOSL2, FOXP2, GABPA, GABPB1, GATA1, HNF4A, HNF4G, MAX, MYBL2, NFIC, NFKB1, NFYB, PML, POLR2A, RAD21, REST, SIN3A, SP1, SREBF1, SREBF2, TAF1, TCF12, YY1, ZBTB7A   
  *CD40*/rs4810485          chr20   1f      CD40                                                                                POLR2A, NFKB1, NFIC, MEF2C, MEF2A, IRF1, IKZF1, FOXM1, BCL3, BATF                                                                                                                          
  *CCR6*/rs3093023          chr6    1f      CCR6                                                                                                                                                                                                                                                                           Oct_1
  *HLAB*/*MICA*/rs2596565   chr6    1f      BTN3A2, HLA-A, HLA-C, HLA-DPB1, HLA-DQA1, HLA-DQB1, HLA-DRB1, HLA-G, HLA-H, VARSL                                                                                                                                                                                              
  *HLA-DRB1*/rs660895       chr6    1f      HLA-DQA2, HLA-DQA1                                                                  BCLAF1, POLR2A                                                                                                                                                                             
  *GRHL2*/rs678347          chr8    2a                                                                                          YY1, CEBPB, EP300, FOXA2, JUND, STAT3, TCF12, USF2, SIN3A                                                                                                                                  HNF3, Foxa2, FOXF2, Freac-2, Freac-4, FOXA1, HNF3, FOXC1
  *PTPN22*/rs2476601        chr1    2b                                                                                          FOS, STAT3                                                                                                                                                                                 Gabpa, Etv1, Elk1, Erg, Ehf, PU.1
  *LBH*/rs10175798          chr2    2b                                                                                          ATF2, FOXM1, RUNX3, NFIC, SPI1, MEF2A, BATF                                                                                                                                                STAT1:STAT1
  *RBPJ*/rs874040           chr4    2b                                                                                          GATA2, PML, TAL1                                                                                                                                                                           MEF-2
  *C5orf30*/rs26232         chr5    2b                                                                                          BHLHE40, CHD1, EP300, FOXM1, MAZ, NFATC1, NFIC, RUNX3, TBL1XR1, TBP, USF2, ATF2, MEF2A, MEF2C, NFKB1                                                                                       ICSBP
  *RUNX1*/rs9979383         chr21   3a                                                                                          MYC, NFKB1                                                                                                                                                                                 E47, FIGLA, ID4, MESP1, SNAI2
  *CTLA4*/rs3087243         chr2    3a                                                                                          MAX, FOS, STAT3                                                                                                                                                                            Bbx
  *IRF5*/rs10488631         chr7    3a                                                                                          GATA2                                                                                                                                                                                      Nanog

[^1]: Academic Editor: Wen-Jun Tu
